According to broker Shore Capital, Poolbeg Pharma PLC (AIM: POLB) is making significant progress toward becoming a rare disease company.
Analysts noted that the lead program, POLB 001, is set to be the first approved therapy providing both prevention and treatment options to mitigate cytokine storms in patients undergoing cancer immunotherapy.
They underscored the potential impact of POLB 001, which could play a crucial role in expanding access to immunotherapy, alleviating hospital bed shortages, lowering costs, and bringing hope to the industry.
Shore Capital pointed out that while cytokine release syndrome (CRS) may not be classified as a rare disease, patients receiving T cell-engaging therapies mainly suffer from rare or orphan blood cancers, representing a market worth US$10 billion.
The broker stated that POLB 001 is well-positioned to tap into this market, and the option agreement for Behçet’s disease further enhances its focus on rare diseases.
Additionally, other programs are targeting critical unmet needs in areas such as obesity and infectious diseases.
